Issue Date: July 17, 2017
U.S. House of Representatives passes FDA user-fee bill
The U.S. House of Representatives cleared a bill on July 12 that reauthorizes the Food & Drug Administration to collect fees from companies to pay for reviews of new drugs and medical devices through fiscal 2022. The legislation now awaits a vote by the Senate, which is expected to pass it before lawmakers go on recess in August.
H.R. 2430 represents months of negotiations among FDA, the medical products industry, and Congress. The bipartisan bill . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society